Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model.
Level 5 - mechanism / opinion, no new human data
Animal and ex vivo laboratory research without human subjects.
PubMed 25213836 · doi:10.1186/s13041-014-0065-y
What was done
Researchers administered magnesium-L-threonate (MgT) to APPswe/PS1dE9 transgenic Alzheimer's disease model mice, including mice at advanced stages of disease progression. They evaluated cognitive performance, amyloid-beta plaque accumulation, synapse density, amyloid precursor protein (APP) metabolism markers (BACE1, sAPPβ, β-CTF), NMDAR signaling, and calcineurin activation in hippocampal brain slices.
What was found
The abstract reports no numerical data. Qualitatively, MgT treatment reduced amyloid-beta plaques, prevented synapse loss, and reversed memory decline, even when initiated at the end-stage of pathological progression. Mechanistically, MgT stabilized BACE1 expression, lowered sAPPβ and β-CTF, and protected synaptic NMDARs against amyloid-beta-induced reductions by preventing calcineurin overactivation.
Why it matters
The findings demonstrate that elevating brain magnesium via magnesium-L-threonate can preserve synaptic integrity and reduce amyloid pathology in transgenic mice, identifying a potential mechanism for cognitive protection in neurodegenerative models.
Limits
The study was conducted entirely in transgenic mice and ex vivo brain slices; efficacy and safety cannot be directly assumed for human Alzheimer's disease. The abstract omits sample sizes, dosages, specific cognitive test scores, and numerical effect sizes.
Cited by
- supports In mouse models, magnesium threonate at a human equivalent dose of 8.1 mg/kg body weight improves cognition and reduces amyloid-beta plaques.